GlaxoSmithKline (GSK) was downgraded to a Hold Rating at Jefferies
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Indian Television Dot Com6h
Fireside Ventures appoints Adarsh Menon as operating partner
Mumbai: On 12 November 2024, Fireside Ventures, an early-stage venture fund focused on consumer brands, appointed Adarsh ...
GlaxoSmithKline (GSK) Receives a Hold from Kepler Capital
Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...
Haleon: Too Vanilla For My Liking - I See Why GSK & Pfizer Wanted Out
Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...
New York Post on MSN4d
FDA proposes ending use of popular decongestant in cold medicines
The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
Ineffective cough syrup ingredient should be axed officially, FDA says
Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused ... or remove such drugs from the market. The Consumer Healthcare ...
Luckie Appoints Chief AI Officer
Luckie & Co. has announced the appointment of Mark Unrein to Chief AI Officer (CAIO). In this new role for the company, Mark ...
Yahoo Finance5d
OMRON Healthcare Announces North America Leadership Transition, Appoints Alice Koehler Managing Director
"OMRON Healthcare continues ... with global brands including GlaxoSmithKline, Kraft Foods and Butterball. She brings a proven ...
Lincoln Journal Star12d
Fewer companies seeking Nebraska tax incentive deals
According to two reports released Thursday by the Nebraska Department of Revenue, the state signed fewer than 40 tax ...
Sensodyne-maker Haleon posts unexpected drop in revenue on weak demand for its painkiller
(Reuters) -Haleon posted an unexpected drop in third-quarter revenue on Thursday, hurt by a weak demand for its painkiller in ...
Haleon Backs Guidance Despite Revenue, Profit Miss
Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts.